A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
A phase I study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer
Danny Rischin,Kailash Narayan,Amit M. Oza,Linda Mileshkin,David Bernshaw,K. Hanlon,Bev McClure,Anthony Fyles +7 more
TL;DR: The aim of this phase I study was to develop a better tolerated regimen that added TPZ to the standard regimen of radiation and weekly low dose CIS.
Proceedings ArticleDOI
2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine
Ana Oaknin,Domenica Lorusso,Amit M. Oza,Nicoletta Colombo,Toon Van Gorp,David M. O'Malley,Sw. Banerjee,Conleth G. Murphy,Philipp Harter,Gottfried E. Konecny,Marie-Christine Kaminsky,Michael Method,Jiuzhou Wang,Robert E. Coleman,Michael J. Birrer,Ursula A. Matulonis,Kathleen N. Moore +16 more
TL;DR: In this paper , the authors characterize the patients with FRα-positive recurrent ovarian cancer who achieved extended treatment benefit (ETB); progression-free survival for 12 months) with MIRV monotherapy.
Journal ArticleDOI
Corrigendum: Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective
TL;DR: This research presents a novel probabilistic procedure called “spot-spot analysis” that allows for real-time analysis of the response of the immune system to foreign substance abuse.
Journal ArticleDOI
Risk-stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program for women with advanced gynecological cancer.
Yeh Chen Lee,Stephanie Lheureux,Nazlin Jivraj,Catherine O'Brien,Stephane Laframboise,Lisa Tinker,Toral Patel,Terri Stuart-McEwan,Pamela Savage,Alexandra M. Easson,Jennifer Croke,Jenny Lau,Eran Shlomovitz,Tanya Chawla,Johane P. Allard,Sarah Buchanan,Pamela Ng,Katherine Karakasis,Amit M. Oza +18 more
TL;DR: Management of MBOs in gynecologic oncology patients is associated with poor prognosis, debilitating symptoms and compromises quality of life.
Journal ArticleDOI
Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory colorectal carcinoma
TL;DR: The combination of dalteparin, prednisone and capecitabine did not improve disease control over that seen with cape citabine in refractory metastatic colorectal cancer.